GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bloomios Inc (OTCPK:BLMS) » Definitions » EPS without NRI

Bloomios (Bloomios) EPS without NRI : $-0.82 (TTM As of Sep. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Bloomios EPS without NRI?

Bloomios's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.82.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -516.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Bloomios's EPS without NRI or its related term are showing as below:

BLMS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -516.9   Med: -227.1   Max: 90.4
Current: -516.9

During the past 10 years, Bloomios's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 90.40% per year. The lowest was -516.90% per year. And the median was -227.10% per year.

BLMS's 3-Year EPS without NRI Growth Rate is ranked worse than
99.88% of 843 companies
in the Drug Manufacturers industry
Industry Median: 9.2 vs BLMS: -516.90

Bloomios's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.26.

Bloomios's EPS (Basic) for the three months ended in Sep. 2023 was $-0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.26.


Bloomios EPS without NRI Historical Data

The historical data trend for Bloomios's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomios EPS without NRI Chart

Bloomios Annual Data
Trend Jun02 Jun03 Jun04 Jan05 Jan06 Jan07 Jan19 Jan20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 - - -0.18 -0.94

Bloomios Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.59 -0.11 -0.09 -0.02

Competitive Comparison of Bloomios's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bloomios's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bloomios's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Bloomios's PE Ratio without NRI falls into.



Bloomios EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bloomios  (OTCPK:BLMS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bloomios EPS without NRI Related Terms

Thank you for viewing the detailed overview of Bloomios's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Bloomios (Bloomios) Business Description

Traded in Other Exchanges
N/A
Address
701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101
Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.
Executives
Douglas S Rohrer officer: Chief Business Officer 701 ANACAPA, SUITE C, SANTA BARBARA CA 93101
Emc2 Capital Llc 10 percent owner 201 W MONTECITO STREET, SANTA BARBARA CA 93101
Barrett Evans director, 10 percent owner, officer: Pres, Chief Strategy Officer
Aline Hayuta Elkayam 10 percent owner 104 CHELSEA PLACE, ORMOND BEACH FL 32174
Bibi Daprile 10 percent owner 12 WINDING CREEK WAY, ORMOND BEACH FL 32174
Agpl Acquisition, Inc 10 percent owner 201 W MONTECITO ST., SANTA BARBARA CA 93101
Mammoth Crest Capital Llc 10 percent owner 1712 PIONEER AVE, SUITE 558, CHEYENNE WY 82001
Michael Hill director, 10 percent owner, officer: Chief Executive Officer 201 WEST MONTECITO STREET, SANTA BARBARA CA 93101
Bryan Glass director, 10 percent owner, officer: President and Director 20 WEST PARK AVENUE, SUITE 207, LONG BEACH NY 11561
Douglas Boyd director, officer: Chairman of the Board 8101 TIARA COVE CIR, LAS VEGAS NV 89128
Peter A Hogendoorn director, officer: President & CEO 13288 AMBLE GREEN PLACE, SURREY A1 V4A 6P5
Harold C Moll director, 10 percent owner
Van Laare Derek R officer: Secretary 6119 GORDON AVENUE, BURNABY A1 V5E 3M2
Carlo Civelli other: former director/officer/owner 111 SOMERSET ROAD, TRIPLE ONE SOMERSET 06-06, SINGAPORE U0 238164
Logan Anderson director, officer: President & Treasurer 15 HILL CRESCENT, PEMBROKE BERMUDA D8 00000